JAMA Clinical Reviews
Preexposure Prophylaxis (PrEP) Options for HIV
Oct 14, 2024
Monica Gandhi, an infectious diseases specialist and professor at UCSF, dives into the world of preexposure prophylaxis (PrEP) for HIV. She discusses the alarming rate of new HIV infections globally and the innovative therapies available, including oral medications and the dapivirine ring, which empowers women in HIV prevention. Gandhi emphasizes the critical role of adherence in maximizing PrEP's effectiveness and shares strategies to improve it. She also advocates for primary care doctors to more widely prescribe PrEP, likening it to the adoption of contraception in healthcare.
14:01
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Effective preexposure prophylaxis (PrEP) options, including oral and injectable forms, are crucial in reducing global HIV infections.
- Improving adherence to PrEP through innovative strategies and increased healthcare provider prescriptions is vital for its overall success.
Deep dives
Understanding PrEP and Its Importance
PrEP, or pre-exposure prophylaxis, is essential for preventing HIV infections, with about 1.3 million new cases reported globally each year. It is recommended for individuals at high risk of HIV, including those with a history of sexually transmitted infections and injection drug users. The availability of effective medications means that PrEP should be a critical component of public health strategies, but many remain unaware of their eligibility for this prevention method. Reaching those at risk is key to significantly reducing the number of new infections worldwide.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
